Zacks Investment Research upgraded shares of ABLYNX (OTCMKTS:ABLYF) from a hold rating to a buy rating in a research report released on Wednesday, November 22nd. They currently have $25.00 target price on the stock.
According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “
Separately, Bank of America started coverage on ABLYNX in a research report on Friday, November 10th. They issued a buy rating and a $26.00 target price for the company.
ABLYNX (ABLYF) remained flat at $$22.15 during trading on Wednesday. ABLYNX has a fifty-two week low of $10.60 and a fifty-two week high of $50.00.
TRADEMARK VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/11/zacks-investment-research-upgrades-ablynx-nv-ablyf-to-buy.html.
Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.
Get a free copy of the Zacks research report on ABLYNX (ABLYF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.